Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection). It is taken by mouth.
Ibrexafungerp is a triterpenoid antifungal.
Ibrexafungerp was approved for medical use in the United States in June 2021. It is the first approved drug in a novel antifungal class.
1 Medical uses